MedTrace Logo

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857649 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 369

Last updated 2013-12-05

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.

Conditions

Interventions

DRUG

Memantine

20 mg Oral Tablets Once Daily

DRUG

Placebo

Oral Tablets Once Daily

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2010-04-30
Completion
2010-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857649 on ClinicalTrials.gov